vs
Side-by-side financial comparison of Hilltop Holdings Inc. (HTH) and Bio-Techne (TECH). Click either name above to swap in a different company.
Hilltop Holdings Inc. is the larger business by last-quarter revenue ($300.5M vs $295.9M, roughly 1.0× Bio-Techne). Hilltop Holdings Inc. runs the higher net margin — 13.0% vs 12.8%, a 0.1% gap on every dollar of revenue. Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 0.6%).
Hilltop Holdings Inc. is a financial holding company based in Dallas, Texas. It offers financial products and banking services through three primary subsidiaries: PlainsCapital Bank, PrimeLending, and HilltopSecurities.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
HTH vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $300.5M | $295.9M |
| Net Profit | $39.0M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 13.0% | 12.8% |
| Revenue YoY | — | -6.4% |
| Net Profit YoY | -12.4% | 68.3% |
| EPS (diluted) | $0.64 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $300.5M | — | ||
| Q4 25 | $329.9M | $295.9M | ||
| Q3 25 | $330.2M | — | ||
| Q2 25 | $303.3M | $317.0M | ||
| Q1 25 | $318.5M | $316.2M | ||
| Q4 24 | $301.1M | $297.0M | ||
| Q3 24 | $305.5M | $289.5M | ||
| Q2 24 | $297.0M | $306.1M |
| Q1 26 | $39.0M | — | ||
| Q4 25 | $41.6M | $38.0M | ||
| Q3 25 | $45.8M | — | ||
| Q2 25 | $36.1M | $-17.7M | ||
| Q1 25 | $42.1M | $22.6M | ||
| Q4 24 | $35.5M | $34.9M | ||
| Q3 24 | $29.7M | $33.6M | ||
| Q2 24 | $20.3M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | 16.1% | 18.4% | ||
| Q3 25 | 18.4% | — | ||
| Q2 25 | 16.3% | -7.5% | ||
| Q1 25 | 18.1% | 12.2% | ||
| Q4 24 | 14.7% | 16.0% | ||
| Q3 24 | 13.9% | 13.8% | ||
| Q2 24 | 10.0% | 15.0% |
| Q1 26 | 13.0% | — | ||
| Q4 25 | 12.6% | 12.8% | ||
| Q3 25 | 13.9% | — | ||
| Q2 25 | 11.9% | -5.6% | ||
| Q1 25 | 13.2% | 7.1% | ||
| Q4 24 | 11.8% | 11.7% | ||
| Q3 24 | 9.7% | 11.6% | ||
| Q2 24 | 6.8% | 13.3% |
| Q1 26 | $0.64 | — | ||
| Q4 25 | $0.68 | $0.24 | ||
| Q3 25 | $0.74 | — | ||
| Q2 25 | $0.57 | $-0.11 | ||
| Q1 25 | $0.65 | $0.14 | ||
| Q4 24 | $0.55 | $0.22 | ||
| Q3 24 | $0.46 | $0.21 | ||
| Q2 24 | $0.31 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | $990.8M | $260.0M |
| Stockholders' EquityBook value | $2.2B | $2.0B |
| Total Assets | $15.7B | $2.5B |
| Debt / EquityLower = less leverage | 0.46× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M |
| Q1 26 | $990.8M | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $2.0B | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.2B | $1.9B | ||
| Q1 25 | $2.2B | $2.0B | ||
| Q4 24 | $2.2B | $2.1B | ||
| Q3 24 | $2.2B | $2.1B | ||
| Q2 24 | $2.1B | $2.1B |
| Q1 26 | $15.7B | — | ||
| Q4 25 | $15.8B | $2.5B | ||
| Q3 25 | $15.6B | — | ||
| Q2 25 | $15.4B | $2.6B | ||
| Q1 25 | $15.8B | $2.6B | ||
| Q4 24 | $16.3B | $2.7B | ||
| Q3 24 | $15.9B | $2.7B | ||
| Q2 24 | $15.6B | $2.7B |
| Q1 26 | 0.46× | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HTH
| Noninterest Income | $188.4M | 63% |
| Net Interest Income | $112.1M | 37% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
